Dante Dallari1, Luigi Zagra2, Pietro Cimatti1, Nicola Guindani3, Rocco D'Apolito4, Federico Bove5, Alessandro Casiraghi6, Fabio Catani7, Fabio D'Angelo8, Massimo Franceschini9, Alessandro Massè10, Alberto Momoli11, Mario Mosconi12, Flavio Ravasi13, Fabrizio Rivera14, Giovanni Zatti15, Claudio Carlo Castelli3. 1. Reconstructive Orthopaedic Surgery and Innovative Techniques-Musculoskeletal Tissue Bank, IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, 40136, Bologna, Italy. 2. IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi 4, 20161, Milan, Italy. luigi.zagra@fastwebnet.it. 3. Department of Orthopaedic Surgery, ASST Papa Giovanni XXIII, Piazza OMS 1, 24127, Bergamo, Italy. 4. IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi 4, 20161, Milan, Italy. 5. Department of Orthopaedic Surgery, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162, Milan, Italy. 6. Department of Orthopaedic Surgery, ASST Degli Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy. 7. Department of Orthopaedic Surgery, Policlinico Universitario di Modena, Via del Pozzo 71, 41124, Modena, Italy. 8. Division of Orthopaedics and Traumatology, ASST Dei Sette Laghi, Department of Biotechnology and Life Sciences (DBSV), University of Insubria, Viale L. Borri 57, 21100, Varese, Italy. 9. ASST Gaetano Pini- CTO, Piazza A. Ferrari 1, 20122, Milan, Italy. 10. Department of Orthopaedic Surgery Ospedale Città Della Salute e Della Scienza, Università di Torino, Via G. Zuretti 29, 10126, Turin, Italy. 11. Department of Orthopaedic Surgery Ospedale San Bortolo, Viale F. Rodolfi 37, 36100, Vicenza, Italy. 12. Department of Orthopaedic Surgery, IRCCS Policlinico San Matteo di Pavia, Viale C. Golgi 19, 27100, Pavia, Italy. 13. Department of Orthopaedic Surgery, ASST Melegnano Martesana-Ospedale di Vizzolo Predabissi, Via Pandina 1, 20077, Vizzolo Predabissi, Italy. 14. Department of Orthopaedic Surgery Ospedale SS Annunziata, Via Ospedali 14, 12038, Savigliano, Italy. 15. Department of Orthopaedic Surgery ASST di Monza, Università Milano Bicocca, Via Pergolesi 33, 20900, Monza, Italy.
Abstract
BACKGROUND: Treatment of hip fractures during the coronavirus disease 2019 (COVID-19) pandemic has posed unique challenges for the management of COVID-19-infected patients and the maintenance of standards of care. The primary endpoint of this study is to compare the mortality rate at 1 month after surgery in symptomatic COVID-positive patients with that of asymptomatic patients. A secondary endpoint of the study is to evaluate, in the two groups of patients, mortality at 1 month on the basis of type of fracture and type of surgical treatment. MATERIALS AND METHODS: For this retrospective multicentre study, we reviewed the medical records of patients hospitalised for proximal femur fracture at 14 hospitals in Northern Italy. Two groups were formed: COVID-19-positive patients (C+ group) presented symptoms, had a positive swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and received treatment for COVID-19; COVID-19-negative patients (C- group) were asymptomatic and tested negative for SARS-CoV-2. The two groups were compared for differences in time to surgery, survival rate and complications rate. The follow-up period was 1 month. RESULTS: Of the 1390 patients admitted for acute care for any reason, 477 had a proximal femur fracture; 53 were C+ but only 12/53 were diagnosed as such at admission. The mean age was > 80 years, and the mean American Society of Anesthesiologists (ASA) score was 3 in both groups. There was no substantial difference in time to surgery (on average, 2.3 days for the C+ group and 2.8 for the C- group). As expected, a higher mortality rate was recorded for the C+ group but not associated with the type of hip fracture or treatment. No correlation was found between early treatment (< 48 h to surgery) and better outcome in the C+ group. CONCLUSIONS: Hip fracture in COVID-19-positive patients accounted for 11% of the total. On average, the time to surgery was > 48 h, which reflects the difficulty of maintaining normal workflow during a medical emergency such as the present pandemic and notwithstanding the suspension of non-urgent procedures. Hip fracture was associated with a higher 30-day mortality rate in COVID-19-positive patients than in COVID-19-negative patients. This fact should be considered when communicating with patients and/or their family. Our data suggest no substantial difference in hip fracture management between patients with or without COVID-19 infection. In this sample, the COVID-19-positive patients were generally asymptomatic at admission; therefore, routine screening is recommended. LEVEL OF EVIDENCE: Therapeutic study, level 4.
BACKGROUND: Treatment of hip fractures during the coronavirus disease 2019 (COVID-19) pandemic has posed unique challenges for the management of COVID-19-infectedpatients and the maintenance of standards of care. The primary endpoint of this study is to compare the mortality rate at 1 month after surgery in symptomatic COVID-positive patients with that of asymptomatic patients. A secondary endpoint of the study is to evaluate, in the two groups of patients, mortality at 1 month on the basis of type of fracture and type of surgical treatment. MATERIALS AND METHODS: For this retrospective multicentre study, we reviewed the medical records of patients hospitalised for proximal femur fracture at 14 hospitals in Northern Italy. Two groups were formed: COVID-19-positive patients (C+ group) presented symptoms, had a positive swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and received treatment for COVID-19; COVID-19-negative patients (C- group) were asymptomatic and tested negative for SARS-CoV-2. The two groups were compared for differences in time to surgery, survival rate and complications rate. The follow-up period was 1 month. RESULTS: Of the 1390 patients admitted for acute care for any reason, 477 had a proximal femur fracture; 53 were C+ but only 12/53 were diagnosed as such at admission. The mean age was > 80 years, and the mean American Society of Anesthesiologists (ASA) score was 3 in both groups. There was no substantial difference in time to surgery (on average, 2.3 days for the C+ group and 2.8 for the C- group). As expected, a higher mortality rate was recorded for the C+ group but not associated with the type of hip fracture or treatment. No correlation was found between early treatment (< 48 h to surgery) and better outcome in the C+ group. CONCLUSIONS:Hip fracture in COVID-19-positive patients accounted for 11% of the total. On average, the time to surgery was > 48 h, which reflects the difficulty of maintaining normal workflow during a medical emergency such as the present pandemic and notwithstanding the suspension of non-urgent procedures. Hip fracture was associated with a higher 30-day mortality rate in COVID-19-positive patients than in COVID-19-negative patients. This fact should be considered when communicating with patients and/or their family. Our data suggest no substantial difference in hip fracture management between patients with or without COVID-19infection. In this sample, the COVID-19-positive patients were generally asymptomatic at admission; therefore, routine screening is recommended. LEVEL OF EVIDENCE: Therapeutic study, level 4.
Entities:
Keywords:
COVID-19; Cephalomedullary nail; Coronavirus; Hip arthroplasty; Neck of the femur; Osteosynthesis; Pertrochanteric fractures; Proximal femur; SARS-CoV-2
Authors: Daniel Pincus; Bheeshma Ravi; David Wasserstein; Anjie Huang; J Michael Paterson; Avery B Nathens; Hans J Kreder; Richard J Jenkinson; Walter P Wodchis Journal: JAMA Date: 2017-11-28 Impact factor: 56.272
Authors: Francesco Benazzo; Stefano Marco Paolo Rossi; Pietro Maniscalco; Biagio Moretti; Enrico Vaienti; Pietro Ruggieri; Alessandro Massè; Antonio Medici; Alessandro Formica; Bruno Di Maggio; Vincenzo Caiaffa; Mario Mosconi; Luigi Murena; Fabio D'Angelo; Alberto Belluati; Emilio Luigi Mazza; Fabrizio Rivera; Alberto Castelli; Matteo Ghiara; Marco Rosolani; Raffaele Cioffi; Raffaele Pezzella; Gabriele Scaravilli; Giovanni Bove; Placido Stissi; Michael Mazzacane; Fabrizio Quattrini; Corrado Ciatti; Giulia Trovarelli; Elisa Pala; Andrea Angelini; Francesco Sanna; Daniela Nonne; Andrea Colombelli; Filippo Raggini; Agnese Puzzo; Gianluca Canton; Guido Maritan; Angela Iuliano; Pietro Randelli; Giuseppe Solarino; Lorenzo Moretti; Giovanni Vicenti; Nunzia Garofalo; Vittorio Nappi; Simone Ripanti; Carmela Chinni; Francesco Pogliacomi; Alberto Visigalli; Nathalie Bini; Alessandro Aprato; Loris Perticarini Journal: Int Orthop Date: 2020-06-26 Impact factor: 3.075
Authors: Christian Thomas Pollmann; Jan Harald Røtterud; Jan-Erik Gjertsen; Fredrik Andreas Dahl; Olav Lenvik; Asbjørn Årøen Journal: BMC Musculoskelet Disord Date: 2019-05-24 Impact factor: 2.362
Authors: Francesco Luceri; Ilaria Morelli; Riccardo Accetta; Laura Mangiavini; Nicola Maffulli; Giuseppe M Peretti Journal: J Orthop Surg Res Date: 2020-08-14 Impact factor: 2.359